Shell Asset Management Co. Lowers Holdings in United Therapeutics Corporation $UTHR

Shell Asset Management Co. decreased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 83.0% during the third quarter, HoldingsChannel.com reports. The firm owned 394 shares of the biotechnology company’s stock after selling 1,917 shares during the quarter. Shell Asset Management Co.’s holdings in United Therapeutics were worth $165,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. WealthCollab LLC lifted its stake in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its position in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the last quarter. Wilmington Savings Fund Society FSB increased its holdings in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares in the last quarter. Abich Financial Wealth Management LLC purchased a new position in United Therapeutics in the 3rd quarter worth about $44,000. Finally, Geneos Wealth Management Inc. raised its position in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on UTHR shares. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research note on Wednesday, October 29th. Jefferies Financial Group restated a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a report on Wednesday, November 19th. Royal Bank Of Canada boosted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. UBS Group restated a “buy” rating on shares of United Therapeutics in a research note on Tuesday. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $509.50.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $476.05 on Thursday. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99. The company’s fifty day simple moving average is $485.84 and its 200-day simple moving average is $437.55. The stock has a market capitalization of $20.50 billion, a PE ratio of 18.04, a P/E/G ratio of 2.57 and a beta of 0.85.

Insiders Place Their Bets

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $479.91, for a total transaction of $10,797,975.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 450,714 shares of company stock worth $218,011,238 in the last quarter. 10.30% of the stock is currently owned by insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.